Vaxcyte, Inc. (PCVX) · Nov 4, 2026 · Earnings

Vaxcyte earnings widen losses as $1.1B raise funds VAX-31

Funding secured — ~$1.1B net proceeds; ~$3.4B pro forma cash

Vaxcyte’s earnings show sharply higher R&D spending and losses, while a $1.1B financing materially extends funding for VAX-31’s regulatory and manufacturing push.

Vaxcyte is moving from a clinical-stage vaccine developer toward a potential commercial launch of VAX-31, its broad-spectrum pneumococcal vaccine, with the adult Phase 3 program largely enrolled and a planned BLA submission targeted for the first half of 2028. That trajectory was already established before this filing: OPUS-1’s positive topline result was announced in October, after the company had narrowed timing for that readout to the end of October.

The business story is funded, not fundamentally changed. The October equity and convertible-note offerings produced approximately $1.1 billion in net proceeds, taking pro forma cash, cash equivalents and investments to approximately $3.4 billion as of September 30. (Business update — financing) This gives Vaxcyte substantially more room to finance the remaining adult trials, the infant study, manufacturing scale-up and potential launch preparation without an immediate funding constraint. The financing itself was already disclosed after the OPUS-1 readout, so the filing mostly confirms its balance-sheet effect rather than delivering a fresh clinical surprise.

Spending is rising because Vaxcyte is advancing, but the burn is becoming more material. Third-quarter R&D expense increased to $270.3 million from $209.9 million, driven by OPUS Phase 3 trials, product manufacturing and launch-related preparation. (Financial results — R&D expenses) The higher loss is therefore consistent with an advancing late-stage program rather than an operating setback, but it also means the newly raised capital is being used to support a substantially more expensive phase of development.

The key clinical proof point is positive but no longer new. VAX-31 met all prespecified primary endpoints in OPUS-1 and showed a safety profile similar to PCV20 and PCV21 across the studied age groups. (Business update — OPUS-1) 〔0〕 However, the comparison is not completely clean: VAX-31 met the stricter individual noninferiority bar for 20 of 20 serotypes shared with PCV20 but 17 of 19 shared with PCV21, with serotypes 3 and 12F falling short of the stricter PCV21 threshold while clearing the historical threshold. (Business update — OPUS-1 comparator analyses) That leaves the PCV21 comparison as a regulatory focus rather than a fully settled advantage.

The next value-bearing milestones remain ahead. OPUS-2 and OPUS-3 results are expected in the first half of 2027, while infant Phase 2 data are expected by the end of the first half of 2027 and the BLA is targeted for the first half of 2028. (Business update — clinical milestones) 〔1〕 These dates preserve the existing development timetable; they do not pull the company materially closer than investors already understood.

Bottom line: This is a funding-and-execution update, not a new clinical inflection point. The larger cash balance modestly strengthens Vaxcyte’s path toward VAX-31 commercialization, but rising losses and unresolved PCV21 regulatory scrutiny keep the core story dependent on the 2027 trial readouts and eventual FDA review.

What to watch next

OPUS-2 and OPUS-3 results, first half 2027

Original filing on SEC EDGAR

More Vaxcyte, Inc. news

• Vaxcyte financing closes at $1.1B ahead of VAX-31 data
• Vaxcyte Phase 3 data clear endpoints, but PCV21 gaps remain
• Vaxcyte tightens VAX-31 readout timing, adds veteran vaccine leadership